Glaxo eyes token profit on malaria vaccine

GlaxoSmithKline hopes to seek approval by 2012 for its experimental vaccine to prevent malaria and will seek only a small profit on the product in order to make it widely available in hard-hit countries, the company said. "(Its) sales in d